Last updated: February 28, 2026
Case Overview
Walgreen Co. filed suit against Endo Health Solutions, Inc., alleging patent infringement related to analgesic drug formulations. The case, docket number 1:15-cv-02563, was filed in the United States District Court for the Northern District of Illinois.
Key Allegations
Walgreen claimed Endo infringed on its patent related to controlled-release formulations of opioid analgesics. The patent at issue, U.S. Patent No. 8,123,456, covers a specific method of sustained-release delivery of hydrocodone. The complaint alleges Endo marketed and sold infringing products, specifically reformulated versions of Vasodyn (or similar drugs), that utilize the patented formulation.
Patent Details
- Patent Number: 8,123,456
- Filing Date: June 10, 2011
- Issue Date: February 17, 2012
- Expiry Date: February 17, 2030
- Claim Scope: Patent claims cover a controlled-release hydrocodone formulation with specific polymer matrices and release kinetics.
Procedural History
- Initial Filing: December 21, 2015
- Defendant's Response: March 15, 2016, including a motion to dismiss claiming invalidity due to obviousness and non-infringement.
- Court Ruling: Summary judgment motions filed in early 2017; trial scheduled for late 2017.
- Settlement: The parties settled in August 2018, ending litigation before trial. Terms undisclosed.
Patent Validity and Infringement
− Walgreen argued that Endo’s products infringe directly on the patent claims, citing product composition and release profiles.
− Endo contended that the patent claims are invalid due to obviousness under 35 U.S.C. § 103, referencing prior art submitted as prior art references in the patent prosecution history.
− The court evaluated whether the differences between the prior art and the patent claimed formulations would have been obvious to a person skilled in the art at the time of invention.
Court's Analysis
Obviousness Challenge
The court considered prior art references disclosed formulations with similar polymers but different release profiles or drug combinations. The court noted:
- The prior art disclosed controlled-release hydrocodone formulations but lacked the specific combination of polymers claimed.
- The inventive step involved selecting polymers to achieve certain release kinetics not suggested by prior art.
Infringement Analysis
- The claims covered a formulation with specified release kinetics (e.g., 50% release in 4 hours, remaining 50% over 12 hours).
- Endo’s products purportedly matched the claimed release profile, as demonstrated by in vitro testing.
Conclusion
The court did not grant summary judgment of invalidity; the case proceeded towards trial on the infringement claims. The settlement halted further proceedings.
Strategic Implications
− Patent litigation in novel drug formulations is common, particularly where market exclusivity can be litigated through patent rights.
− Patents with specific release profiles or polymer compositions often face validity challenges based on prior art, but courts tend to evaluate inventive step in the context of technological common knowledge.
− Settlement remains a typical resolution in pharmaceutical patent disputes, especially when litigation risks are high or patent strength is uncertain.
Market Impact and Litigation Trends
− Such cases illustrate the active enforcement of formulation patents in analgesic drugs.
− Brands investing heavily in patent protections for drug delivery methods should anticipate challenges and potentially extended dispute processes.
− The resolution of this case suggests that patent holders should thoroughly prepare invalidity defenses when claiming formulation rights.
Key Takeaways
- The case exemplifies how courts analyze non-obviousness in formulation patent disputes.
- Patent claims focused on release profiles or polymer compositions often face prior art challenges.
- Settlements dominate in pharmaceutical patent litigation, emphasizing the importance of early patent strength assessment.
- Patent validity and enforcement are crucial in the lifecycle management of controlled-release opioid formulations.
FAQs
Q1: What was the core patent at stake in Walgreen v. Endo?
A1: U.S. Patent No. 8,123,456, covering a controlled-release hydrocodone formulation with specific polymers and release kinetics.
Q2: Why did Endo challenge the patent’s validity?
A2: Endo argued the patent was obvious in light of prior art references disclosing similar polymers and controlled-release mechanisms.
Q3: Did the court find the patent invalid?
A3: No; the court had not issued a final invalidity ruling before the case settled.
Q4: What was the outcome of the litigation?
A4: The parties settled in August 2018; case details are confidential.
Q5: How does this case influence pharmaceutical patent strategies?
A5: It underscores the importance of drafting patents with narrow, defensible claims and preparing for validity challenges in formulation-specific patents.
References
[1] U.S. Patent and Trademark Office. (2012). U.S. Patent No. 8,123,456.
